Skip to main
SGMT

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences Inc. is advancing its clinical-stage drug candidate, denifanstat, for the treatment of nonalcoholic steatohepatitis (NASH), positioned as a selective fatty acid synthase (FASN) inhibitor. The favorable safety profile observed in Phase II studies enhances denifanstat's potential as a viable option for combination therapies, which may bolster its therapeutic applicability. Additionally, preclinical studies have indicated additive efficacy in reducing liver fat and improving fibrosis when denifanstat is used alongside resmetirom, suggesting strong potential for optimized treatment strategies within a significant market segment.

Bears say

Sagimet Biosciences Inc faces a potential negative outlook primarily due to high turnover in key regulatory agency-facing roles, such as the CEO and CMO, which could undermine investor confidence and negatively affect share performance. Additionally, any issues related to the efficacy or safety of its clinical development programs, especially regarding the drug candidate denifanstat for treating NASH, could further diminish the stock's value. The combination of leadership instability and clinical trial risks presents significant challenges that could adversely impact the company's financial stability and market perception.

SGMT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Strong Buy based on their latest research and market trends.

According to 6 analysts, SGMT has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.